Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from Ascelia Pharma AB ( (SE:ACE) ).
Ascelia Pharma AB has called its annual general meeting for 4 May 2026 in Malmö, inviting shareholders of record as of 23 April 2026 to participate in person or by proxy. Shareholders with nominee-registered shares must ensure voting rights registration by 27 April 2026 to exercise their votes at the meeting.
The agenda includes standard corporate governance items such as election of the chair, board and auditor appointments, approval of financial statements and the remuneration report, and guidelines for executive pay. The board also proposes no dividend, with SEK 13.4 million in available funds to be carried forward, and plans to seek shareholder approval for new share-related authorizations and a long-term performance-based incentive program.
The most recent analyst rating on (SE:ACE) stock is a Hold with a SEK3.00 price target. To see the full list of analyst forecasts on Ascelia Pharma AB stock, see the SE:ACE Stock Forecast page.
More about Ascelia Pharma AB
Ascelia Pharma AB is a Swedish pharmaceutical company based in Malmö, focused on developing specialty oncology treatments. The company targets niche patient populations with unmet medical needs, positioning itself within the broader life sciences and biotech sector in Scandinavia and Europe.
YTD Price Performance: -10.26%
Average Trading Volume: 805,172
Technical Sentiment Signal: Sell
Current Market Cap: SEK366M
For an in-depth examination of ACE stock, go to TipRanks’ Overview page.